Search

Stephen M Autenrieth

from Bernardsville, NJ
Age ~73
Get Report
Also known as:
Stephen M Autenriet, Steve M Autenrieth, Stephen U
Phone and address:
18 Columbia Dr, Bernardsville, NJ 07924
(908) 766-3362
Related to:
Judy E Kline, 66Bonnie L Autenrieth, 35Drew N Autenrieth, 38Sara L Autenrieth, 38Wendy M Autenrieth, 31Edith F MooreLois M Autenrieth, 72
Connected to:
Alec M Autenrieth, 40Andrea B Autenrieth, 115Kevin L Autenrieth, 61Olivia F Autenrieth, 39Patricia Y Autenrieth, 67Frank Autera, 56Marlene M Autera, 75Francesco Auteri, 54Melissa M Auteri, 57Pasquale P Auteri, 75

Stephen Autenrieth Phones & Addresses

  • 18 Columbia Dr, Bernardsville, NJ 07924 (908) 766-3362
  • Raritan, NJ
  • 18 Columbia Dr, Bernardsville, NJ 07924 (908) 510-9601

Work

Position: Service Occupations

Education

Degree: Graduate or professional degree

Publications

Us Patents

Capture, Concentration And Quantitation Of Abnormal Prion Protein From Biological Fluids Using Depth Filtration

View page
US Patent:
7201901, Apr 10, 2007
Filed:
May 23, 2003
Appl. No.:
10/444606
Inventors:
Robert W. Van Holten - Flemington NJ, US
Stephen M. Autenrieth - Bernardsville NJ, US
Assignee:
Ortho-Clinical Diagnostics, Inc. - Raritan NJ
International Classification:
A61K 39/00
A23L 1/28
A23J 1/00
US Classification:
4241401, 426425, 530419
Abstract:
Methods for producing biological solutions such as immunoglobulins and in particular anti-D immunoglobulin substantially free of abnormal prion protein resulting therefrom. Specifically provided are methods for aggregation of prions and depth filtration of the biological solution to capture and remove abnormal and if desired, normal prion protein. The prion protein may then be eluted from the depth filter and filter washes and concentrated sufficient for detection at limits currently required by available assays.

Optimal Placement Of A Robust Solvent/Detergent Process Post Viral Ultrafiltration Of An Immune Gamma Globulin

View page
US Patent:
7655233, Feb 2, 2010
Filed:
Nov 15, 2005
Appl. No.:
11/274812
Inventors:
Robert W. Van Holten - Flemington NJ, US
Stephen M. Autenrieth - Bernardsville NJ, US
Assignee:
Ortho-Clinical Diagnostics, Inc. - Rochester NY
International Classification:
A61K 39/00
US Classification:
4241761
Abstract:
The solvent-detergent (S/D) process is used to inactivate enveloped viruses in plasma products. While concentrations of 1. 0% detergent and 0. 3% tri-n-butyl phosphate solvent have been considered necessary for robust removal of viral activity, we show the effectiveness of solvent-detergent treatment after fractionation and nanofiltration of an immune gamma globulin preparation, which required significantly reduced concentrations of solvent and detergent. Reduced levels of solvent and detergent lead to greater efficiencies in their removal post-inactivation with the potential for greater yields and decreased processing costs.

Capture, Concentration And Quantitation Of Abnormal Prion Protein From Biological Fluids Using Depth Filtration

View page
US Patent:
20070148685, Jun 28, 2007
Filed:
Feb 13, 2007
Appl. No.:
11/674368
Inventors:
Robert Van Holten - Flemington NJ, US
Stephen Autenrieth - Bernardsville NJ, US
International Classification:
C12Q 1/68
G01N 33/53
US Classification:
435006000, 435007100
Abstract:
Methods for producing biological solutions such as immunoglobulins and in particular anti-D immunoglobulin substantially free of abnormal prion protein resulting therefrom. Specifically provided are methods for aggregation of prions and depth filtration of the biological solution to capture and remove abnormal and if desired, normal prion protein. The prion protein may then be eluted from the depth filter and filter washes and concentrated sufficient for detection at limits currently required by available assays.

Optimal Placement Of A Robust Solvent/Detergent Process Post Viral Ultrafiltration Of An Immune Gamma Globulin

View page
US Patent:
20100129893, May 27, 2010
Filed:
Jan 25, 2010
Appl. No.:
12/693335
Inventors:
Robert W. Van Holten - Flemington NJ, US
Stephen M. Autenrieth - Bernardsville NJ, US
International Classification:
C12N 7/06
US Classification:
435238
Abstract:
The solvent-detergent (S/D) process is used to inactivate enveloped viruses in plasma products. While concentrations of 1.0% detergent and 0.3% tri-n-butyl phosphate solvent have been considered necessary for robust removal of viral activity, we show the effectiveness of solvent-detergent treatment after fractionation and nanofiltration of an immune gamma globulin preparation, which required significantly reduced concentrations of solvent and detergent. Reduced levels of solvent and detergent lead to greater efficiencies in their removal post-inactivation with the potential for greater yields and decreased processing costs.

Buffer System In An Anti-Thrombin Iii Test

View page
US Patent:
43025382, Nov 24, 1981
Filed:
May 8, 1980
Appl. No.:
6/147810
Inventors:
Stephen M. Autenrieth - Bernardsville NJ
Raymond P. Zolton - Somerville NJ
Assignee:
Ortho Diagnostics Inc. - Raritan NJ
International Classification:
C12Q 156
US Classification:
435 13
Abstract:
Disclosed is a procedure for conducting anti-thrombin III assays in which the conventional thrombin-anti-thrombin III treatment step is conducted at a pH of 7. 9 to 8. 5 maintained at the level by a buffer system comprising a buffering amount of N-2-hydroxyethylpiperazine-N'-2-ethanesulfonic acid, N-2-hydroxyethylpiperazine-N'-3-propanesulfonic acid, N-tris-(hydroxymethyl)-methyl-2-amino-ethanesulfonic acid, N-tris-(hydroxymethyl)-methylglycine, or N,N-bis (2-hydroxymethyl)-glycine or a salt thereof. The compositions may also contain bacteriostatic agents.

Method Of Determining Levels Of Extrinsic And Intrinsic Clotting Factors And Protein C

View page
US Patent:
51697866, Dec 8, 1992
Filed:
Dec 19, 1989
Appl. No.:
7/452802
Inventors:
James J. Carroll - East Hanover NJ
Stephen M. Autenrieth - Bernardsville NJ
Assignee:
Ortho Diagnostic Systems, Inc. - Raritan NJ
International Classification:
G01N 3316
US Classification:
436 69
Abstract:
A method of determining levels of extrinsic and intrinsic clotting factors and protein C based upon the reaction rate of the observed clot formation and the first derivative of the reaction rate of observed clot formation is provided. In accordance with the teachings of the invention, the reaction rate of the observed clot formation in a prothrombin time test or an activated partial thromboplastin time assay is determined for both test and normal plasma samples and the reaction rates compared. In another embodiment, the first derivative of the reaction rate of the observed clot formation is determined and the results compared.
Control profile
Stephen M Autenrieth from Bernardsville, NJ, age ~73 Get Report